Advanced breast cancer with remarkable response to the combination therapy of mitoxantrone (MIT) and medroxyprogesteron acetate (MPA) after failure of anthracycline therapy: a case report

Izumi, M.; Iino, Y.; Yokoe, T.; Inoue, T.; Yamada, T.; Kobayashi, I.; Andoh, T.; Yokota, T.; Iijima, T.; Morishita, Y.

Gan to Kagaku Ryoho. Cancer and ChemoTherapy 21(2): 265-268

1994


ISSN/ISBN: 0385-0684
PMID: 8311500
Document Number: 433433
A 67-year-old advanced breast cancer patient with multiple bone metastases showed a remarkable response to the combination therapy of mitoxantrone (MIT) and medroxyprogesteron acetate (MPA) after failure of anthracycline therapy. Eight course of CTF (cyclophosphamide, THP-adriamycin, 5-fluorouracil) and subsequent 4'-epi-adriamycin were performed for locally advanced breast cancer and multiple bone metastases, but the ulcerated breast cancer enlarged. Then the combination therapy of MIT (10 mg/day) and MPA (1,200 mg/day) was carried out. Seven months after treatment, the ulcerated breast cancer disappeared completely and the serum levels of CA 15-3, TPA and CEA decreased within the normal range. These results suggest that combination therapy with mitoxantrone may well be effective against the anthracycline-resistant breast cancer.

Document emailed within 1 workday
Secure & encrypted payments